MAP2K7 and Miyoshi myopathy: A study published by Robert et al. has shown the superiority of dabrafenib (BRAF inhibitor) combined with trametinib (MEK inhibitor) to monotherapy with vemurafenib (BRAF inhibitor); the overall survival was significantly improved in previously untreated patients with metastatic MM with BRAF mutations who had received BRAF and MEK inhibitors.